Sunday, April 5, 2020

Atrial Fibrillation Market Clinical Reviews and Precise Outlook to 2020


Atrial Fibrillation Market 2012 – 2020 report delivers future development strategies, key companies, Possibility of competition, major challenges analysis. The reports elaborate the expansion rate of the Atrial Fibrillation market supported the highest company profile analysis. This report providing an in-depth analysis, market size, and evaluation for the developing segment among the Atrial Fibrillation market. Atrial Fibrillation Market report will help you take expert decisions, recognize opportunities, plan effective professional tactics, plan new schemes, analyze drivers and restraints and give you a vision on the Atrial Fibrillation Market forecast.
Atrial Fibrillation Market
The scope of the global Atrial Fibrillation Market is projected to touch US$ 16.17 billion by 2020, growing at a CAGR of 13.2% for the duration of the forecast.
This could be attributed to increase in incidences of atrial fibrillation amongst geriatric population, rise in preference for catheter ablation to treat cardiac arrhythmia, and technological advancements. Atrial fibrillation comes across as an irregular or a rapid rhythm pertaining to the heart that, in turn, does increase risk of stroke, cardiovascular diseases, and several other complications like chest pain, discomfort (Angina). The symptoms include dizziness, fainting, fatigue, and confusion.
Key Questions Answered
  • What are the sales or revenue produced by Atrial Fibrillation products beyond all sectors during the forecast period?
  • What are the key trends in the Atrial Fibrillation market?
  • What are the leading drivers, limitations, and probabilities in the industry?
  • Which segment will gain the highest revenue worldwide and which product segment will expand at the fastest CAGR during the forecast period?
  • In which region the Atrial Fibrillation market to project lucrative CAGR during the forecast period?
Regional Insights:
By geography, the atrial fibrillation industry says North America, Europe, Asia Pacific, and LAMEA. North America holds the largest market share due to prevalence of refined healthcare infrastructure in the U.S. and Canada. Europe comes in second due to Denmark and Belgium being the healthcare capitals. Asia Pacific is expected to grow at the fastest rate due to sedentary lifestyle calling for loads of cardiac diseases. Besides, economies like China and India are asking for AF devices; which are likely to put Asia Pacific on the top in the near future.
Market Insights:
Extensive research is being carried out with regards to Atrial fibrillation. Novel treatments like FIRM ablation, Watchman device, and Convergent procedure are seeing success in around 75-80% of patients. Players are also engaging in organic mode of development. For instance – in 2016, Boehringer Ingelheim Pharmaceuticals, Inc., in partnership with Heart Rhythm Society, did award “Atrial Fibrillation (AFib) Quality Improvement (QI) Innovation Grant” to Dr. Steven A. Lubitz (MD, MPH, Massachusetts General Hospital) and Dr. Mark H. Eckman (MD, University of Cincinnati) for encouraging research on preventing atrial fibrillation and stroke.
Players:
The other players contributing to the atrial fibrillation market include CardioFocus, Inc., Osypka AG, Japan Lifeline Co., EndoPhotonix, Inc., CathRx Ltd., Biosense Webster, Inc., TZ Medical, GE Healthcare, and Pioneer Medical Devices AG.

No comments:

Post a Comment